Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Despite tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes, mu, delta and kappa, whose genes have been cloned. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the mu-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of mu receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to delta- or kappa-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the mu-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, in animal models, dopamine D1 receptor knockout rats will not self-administer cocaine37 and μ opioid receptor knockout mice will not show the rewarding effects of opioids.153”
From Neurobiology of addiction: a neurocircuitry analysis (2016) · cites this paper as [153]
In the citing paper
“Mice that lack the MOR gene do not develop place preferences or withdrawal symptoms in response to morphine (Matthes et al 1996).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Matthes et al 1996
Citations
Cites
Kieffer, B. L., Befort, K., Gaveriaux-Ruff, C., & Hirth, C. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12048 · Cited by 1,010
Self-citationNeutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.
Roques, B. P., Noble, F., Daugé, V, Fournié-Zaluski, M. C., & Beaumont, A. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00449-1 · Cited by 756
Self-citationLufkin, T., Dierich, A., LeMeur, M., Mark, M., & Chambon, P. (1991) · Cell · doi:10.1016/0092-8674(91)90034-v · Cited by 697
Self-citationChiara, G. D., & Alan North, R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90062-b · Cited by 543
Terwilliger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M., & Nestler, E. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)91111-d · Cited by 535
A brief history of opiates, opioid peptides, and opioid receptors.
Brownstein, M. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5391 · Cited by 491
Multiple opioid receptors: ligand selectivity profiles and binding site signatures.
Goldstein, A., & Naidu, A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09190-4 · Cited by 445
Kieffer, B. L. (1995) · Cellular and Molecular Neurobiology · doi:10.1007/bf02071128 · Cited by 389
Self-citationReduction of Morphine Abstinence in Mice with a Mutation in the Gene Encoding CREB
Maldonado, R., Blendy, J. A., Tzavara, E., Gass, P., Roques, B. P., Hanoune, J., & Schütz, G. (1996) · Science · doi:10.1126/science.273.5275.657 · Cited by 292
Self-citationThe mouse Pgk-1 gene promoter contains an upstream activator sequence
McBurney, M. W., Sutherland, L. C., Adra, C. N., Leclair, B., Rudnicki, M. A., & Jardine, K. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.20.5755 · Cited by 193
Research works printed but not linked: 9
- Goldstein, A. & Naidu, A. Mol. Pharmacol. 36, 265–272 (1989).
- Pasternak, G. W. Clin. Pharmacol. 16, 1–18 (1993).
- Cowan, A. in Handbook of Experimental Pharmacology Opioids II (ed. Herz, A.) Vol. 104, 393–414 (Springer, Berlin, 1993).
- Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M.-C. & Beaumont, A. Pharmacol. Rev. 45, 87–146 (1993).
- Baamonde, A., Daugé, V., Gacel, C. & Roques, B. P. J. Pharmacol. Exp. Ther. 257, 767–773 (1991).
- Koob, G. F. Trends Biochem. Sci. 13, 177–184 (1992).
- Wei, E. T. J. Pharmacol. Exp. Ther. 216, 12–18 (1981).
- Cowan, A., Zhu, X. Z., Mosberg, H. I., Omnaas, J. R. & Porreca, F. J. Pharmacol. Exp. Ther. 246, 950–955 (1988).
- Kitchen, I. et al. J. Pharmacol. Exp. Ther. 275, 1595–1607 (1995).
Cited by
Items 101–200 of 1,002
The role of the brain reward system in depression
Naranjo, C. A., Tremblay, L. K., & Busto, U. E. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00156-7 · Cited by 245
Identifying genes for alcohol and drug sensitivity: recent progress and future directions
Crabbe, J. C., Phillips, T. J., Buck, K. J., Cunningham, C. L., & Belknap, J. K. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01393-4 · Cited by 247
Befort, K., Filliol, D., Décaillot, F. M., Gavériaux-Ruff, C., Hoehe, M. R., & Kieffer, B. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006352200 · Cited by 242
Self-citationThe endogenous opioid system: A common substrate in drug addiction
Trigo, J. M., Martin-García, E., Berrendero, F., Robledo, P., & Maldonado, R. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.10.011 · Cited by 240
Self-citationCastañé, A., Valjent, E., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00118-1 · Cited by 239
“The rewarding effects of nicotine were evaluated by using the conditioned place preference paradigm, as previously described (Maldonado et al., 1997; Matthes et al., 1996).”
MethodSelf-citationμ-Opposing actions of the κ-opioid receptor
Pan, Z. Z. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01169-9 · Cited by 238
Brain circuits for pain and its treatment
Mercer Lindsay, N., Chen, C., Gilam, G., Mackey, S., & Scherrer, G. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj7360 · Cited by 229
Nocistatin, a peptide that blocks nociceptin action in pain transmission
Okuda-Ashitaka, E., Minami, T., Tachibana, S., Yoshihara, Y., Nishiuchi, Y., Kimura, T., & Ito, S. (1998) · Nature · doi:10.1038/32660 · Cited by 233
Kitchen, I., Slowe, S. J., Matthes, H. W. D., & Kieffer, B. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00988-8 · Cited by 229
Self-citationIncreased Abundance of Opioid Receptor Heteromers After Chronic Morphine Administration
Gupta, A., Mulder, J., Gomes, I., Rozenfeld, R., Bushlin, I., Ong, E., Lim, M., Maillet, E., Junek, M., Cahill, C. M., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000807 · Cited by 226
Ovarian Hormones and Migraine Headache: Understanding Mechanisms and Pathogenesis—Part I
Martin, V. T., & Behbehani, M. (2006) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2006.00309.x · Cited by 227
Berrendero, F., Kieffer, B. L., & Maldonado, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10935.2002 · Cited by 222
“-Opioid receptors also seem to be crucial in mediating rewarding properties of other drugs of abuse such as morphine (Matthes et al., 1996), ethanol (Roberts et al.”
BackgroundMethodInfluentialSelf-citationLeshner, A. I., & Koob, G. F. (1999) · Proceedings of the Association of American Physicians · doi:10.1046/j.1525-1381.1999.09218.x · Cited by 217
Spinal delivery of analgesics in experimental models of pain and analgesia
Fairbanks, C. A. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00101-7 · Cited by 214
Zelcer, N., van de Wetering, K., Hillebrand, M., Sarton, E., Kuil, A., Wielinga, P. R., Tephly, T., Dahan, A., Beijnen, J. H., & Borst, P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502530102 · Cited by 215
Incomplete cross tolerance and multiple mu opioid peptide receptors
Pasternak, G. W. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01616-3 · Cited by 213
Lutfy, K., Eitan, S., Bryant, C. D., Yang, Y. C., Saliminejad, N., Walwyn, W., Kieffer, B. L., Takeshima, H., Carroll, F. I., Maidment, N. T., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10331.2003 · Cited by 211
“-Opioid receptor knock-out and wild-type mice, fully backcrossed to C57BL/6J background, were the offspring of heterozygote mice (Matthes et al., 1996).”
BackgroundSelf-citationEnhanced Rewarding Properties of Morphine, but not Cocaine, in βarrestin-2 Knock-Out Mice
Bohn, L. M., Gainetdinov, R. R., Sotnikova, T. D., Medvedev, I. O., Lefkowitz, R. J., Dykstra, L. A., & Caron, M. G. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-32-10265.2003 · Cited by 210
“…experiments, has been greatly strengthened by the finding that mice lacking the OR do not experience morphine-mediated antinociception, respiratory suppression, inhibition of gastrointestinal transit, or increased locomotor activity (Matthes et al., 1996; Sora et al., 1997; Kieffer, 1999).”
InfluentialChen, X.-T., Pitis, P., Liu, G., Yuan, C., Gotchev, D., Cowan, C. L., Rominger, D. H., Koblish, M., DeWire, S. M., Crombie, A. L., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4010829 · Cited by 208
Nestler, E. J. (2000) · Nature Genetics · doi:10.1038/81570 · Cited by 206
Lötsch, J., Skarke, C., Grösch, S., Darimont, J., Schmidt, H., & Geisslinger, G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200201000-00002 · Cited by 211
Rewarding effects of opiates are absent in mice lacking the receptor for substance P
Murtra, P., Sheasby, A. M., Hunt, S. P., & De Felipe, C. (2000) · Nature · doi:10.1038/35012069 · Cited by 208
Uhl, G. R., Sora, I., & Wang, Z. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7752 · Cited by 206
Regulation of Opioid Receptor Activities
Law, P.-Y., & Loh, H. H. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38179-0 · Cited by 206
Multiple opiate receptors: déjà vu all over again
Pasternak, G. W. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.004 · Cited by 201
Yang, J., Wu, J., Kowalska, M. A., Dalvi, A., Prevost, N., O'Brien, P. J., Manning, D., Poncz, M., Lucki, I., Blendy, J. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180194597 · Cited by 199
Matthes, H. W. D., Smadja, C., Valverde, O., Vonesch, J.-L., Foutz, A. S., Boudinot, E., Denavit-Saubié, M., Severini, C., Negri, L., Roques, B. P., et al. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-18-07285.1998 · Cited by 199
Self-citationModulation of pain transmission by G-protein-coupled receptors
Pan, H.-L., Wu, Z.-Z., Zhou, H.-Y., Chen, S.-R., Zhang, H.-M., & Li, D.-P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.003 · Cited by 194
“Analyses of opioid receptor knockout mice have clearly shown that the μ-opioid receptors play a central role in opioid-induced analgesia (Matthes et al., 1996; Simonin et al., 1998; Zhu et al., 1999).”
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain
Roques, B. P., Fournié-Zaluski, M.-C., & Wurm, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3673 · Cited by 194
Self-citationBasile, A. S., Fedorova, I., Zapata, A., Liu, X., Shippenberg, T., Duttaroy, A., Yamada, M., & Wess, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162371899 · Cited by 195
Hutcheson, D. M., Tzavara, E. T., Smadja, C., Valjent, E., Roques, B. P., Hanoune, J., & Maldonado, R. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702228 · Cited by 192
“Biochemical adaptations to chronic opioid treatment involve a long lasting upregulation of the cyclic AMP pathway after repeated exposure to the drug, as revealed by the marked increase in AC activity during morphine withdrawal (Duman et al., 1988; Matthes et al., 1996).”
BackgroundSelf-citationRaehal, K. M., & Bohn, L. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.08.003 · Cited by 189
“A number of studies have demonstrated that the physiological actions of morphine and other clinically used opiates are mediated primarily through activation of the mu opioid receptor (MOR), a G protein-coupled receptor (Matthes et al., 1996; Sora et al., 1997; Roy et al., 1998; Kieffer et al., 1999).”
BackgroundRegulations of opioid dependence by opioid receptor types
Narita, M., Funada, M., & Suzuki, T. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00099-1 · Cited by 190
Characterization of [Nphe1]nociceptin(1‐13)NH2, a new selective nociceptin receptor antagonist
Calo', G., Guerrini, R., Bigoni, R., Rizzi, A., Marzola, G., Okawa, H., Bianchi, C., Lambert, D. G., Salvadori, S., & Regoli, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703169 · Cited by 190
μ-Opioid Receptor Activates Signaling Pathways Implicated in Cell Survival and Translational Control
Polakiewicz, R. D., Schieferl, S. M., Gingras, A.-C., Sonenberg, N., & Comb, M. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.36.23534 · Cited by 189
Regulation of Opioid Tolerance by let-7 Family MicroRNA Targeting the μ Opioid Receptor
He, Y., Yang, C., Kirkmire, C. M., & Wang, Z. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2419-10.2010 · Cited by 186
Using Knockout and Transgenic Mice to Study Neurophysiology and Behavior
PICCIOTTO, M. R., & WICKMAN, K. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.4.1131 · Cited by 186
Kohno, T., Ji, R.-R., Ito, N., Allchorne, A. J., Befort, K., Karchewski, L. A., & Woolf, C. J. (2005) · Pain · doi:10.1016/j.pain.2005.05.035 · Cited by 185
“opioid receptor (MOR), which is widely expressed in the peripheral and central nervous systems (Matthes et al., 1996).”
BackgroundSelf-citationEndogenous opioid peptides in the descending pain modulatory circuit
Bagley, E. E., & Ingram, S. L. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108131 · Cited by 181
Hartrick, C., Van Hove, I., Stegmann, J.-U., Oh, C., & Upmalis, D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.009 · Cited by 182
Woolf, C. J., & Decosterd, I. (1999) · Pain · doi:10.1016/s0304-3959(99)00148-7 · Cited by 182
“While the power of contemporary preclinical basic science is readily recognized in its success in elucidating the molecular mechanism of the action of current analgesics; the opiates (Keiffer et al., 1992; Matthes et al., 1996) NSAIDS (Mitchell et al.”
BackgroundPain Responses in Methadone-Maintained Opioid Abusers
Compton, P., Charuvastra, V. C., Kintaudi, K., & Ling, W. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00191-3 · Cited by 181
Opioid receptors: From binding sites to visible molecules in vivo
Kieffer, B. L., & Evans, C. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.033 · Cited by 180
“Mu receptors represent the primary molecular target for morphine in vivo and mediate both beneficial and adverse effects of the most broadly used opiate (Matthes et al., 1996).”
BackgroundSelf-citationEndocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors
Serrano, A., & Parsons, L. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.06.005 · Cited by 180
“Opioids, such as heroin and morphine exert their physiological and behavioral effects through specific interactions with mu (μ)-, delta (δ)- and, kappa (κ)-opioid receptors, though opiate dependence appears to primarily involve μ receptors (Kieffer, 1999; Matthes et al., 1996).”
BackgroundInfluentialEndogenous opioids: overview and current issues
Akil, H., Owens, C., Gutstein, H., Taylor, L., Curran, E., & Watson, S. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00071-4 · Cited by 180
Naloxone treatment in opioid addiction: the risks and benefits
van Dorp, E. L., Yassen, A., & Dahan, A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.2.125 · Cited by 179
“Dedicated in vivo studies have shown that mice lacking the μ-opioid receptor (exon 2 μ-opioid receptor gene knockout mice) display less self-administration of morphine and reduced conditioned place preference [5], underlining the importance of the μ-opioid receptor in the development of opioid addiction.”
BackgroundOpioid receptor genes inactivated in mice: the highlights
Gavériaux-Ruff, C., & Kieffer, B. L. (2002) · Neuropeptides · doi:10.1054/npep.2002.0900 · Cited by 178
Self-citationBart, G., Heilig, M., LaForge, K. S., Pollak, L., Leal, S. M., Ott, J., & Kreek, M. J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001504 · Cited by 177
Arias, A., Feinn, R., & Kranzler, H. R. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.11.024 · Cited by 177
Gudin, J., & Fudin, J. (2020) · Pain and Therapy · doi:10.1007/s40122-019-00143-6 · Cited by 172
Cellular mechanism for anti-analgesic action of agonists of the κ-opioid receptor
Pan, Z. Z., Tershner, S. A., & Fields, H. L. (1997) · Nature · doi:10.1038/38730 · Cited by 176
Targeting multiple opioid receptors – improved analgesics with reduced side effects?
Günther, T., Dasgupta, P., Mann, A., Miess, E., Kliewer, A., Fritzwanker, S., Steinborn, R., & Schulz, S. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13809 · Cited by 172
“Clinically used opioids such as morphine require the expression of μ receptors to exert an effect, as shown in μ receptor knock out mice (Matthes et al., 1996).”
BackgroundDopamine neurons projecting to medial shell of the nucleus accumbens drive heroin reinforcement
Corre, J., van Zessen, R., Loureiro, M., Patriarchi, T., Tian, L., Pascoli, V., & Lüscher, C. (2018) · eLife · doi:10.7554/elife.39945 · Cited by 175
Opioids and Their Complicated Receptor Complexes
Jordan, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00143-3 · Cited by 174
“Although morphine exhibits high affinity for both delta and mu receptors, a recent study has shown that mu receptor knockout mice no longer exhibit morphine-induced analgesia (”
BackgroundGreenwald, M. K., Comer, S. D., & Fiellin, D. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.035 · Cited by 174
“In animal studies, μORs have been implicated in opioid reinforcement (Bertalmio and Woods, 1989; Kreek et al., 2012; Matthes et al., 1996), discriminative stimulus effects (Bertalmio and Woods, 1987; Comer et al., 1993; Dykstra et al., 1988; Walker et al., 1994), and withdrawal effects (France and…”
BackgroundExpansion of the human μ-opioid receptor gene architecture: novel functional variants
Shabalina, S. A., Zaykin, D. V., Gris, P., Ogurtsov, A. Y., Gauthier, J., Shibata, K., Tchivileva, I. E., Belfer, I., Mishra, B., Kiselycznyk, C., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddn439 · Cited by 174
Abolition of morphine-immunosuppression in mice lacking the μ-opioid receptor gene
Gavériaux-Ruff, C., Matthes, H. W. D., Peluso, J., & Kieffer, B. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6326 · Cited by 174
Self-citationVela, G., Martı́n, S., Garcı́a-Gil, L., Crespo, J. A., Ruiz-Gayo, M., Javier Fernández-Ruiz, J., Garcı́a-Lecumberri, C., Pélaprat, D., Fuentes, J. A., Ramos, J. A., et al. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00766-5 · Cited by 173
Functional Interactions between μ Opioid and α2A-Adrenergic Receptors
Jordan, B. A., Gomes, I., Rios, C., Filipovska, J., & Devi, L. A. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1317 · Cited by 172
Pain Genes?: Natural Variation and Transgenic Mutants
Mogil, J. S., Yu, L., & Basbaum, A. I. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.777 · Cited by 172
“The same was true when the mu opioid receptor was eliminated; all the other components of the opioid system, including the endogenous peptides, as well as the delta and kappa opioid receptors, showed very little change (Kitchen et al 1997, Matthes et al 1996).”
BackgroundInfluentialAltered Hematopoiesis, Behavior, and Sexual Function in μ Opioid Receptor–deficient Mice
Tian, M., Broxmeyer, H. E., Fan, Y., Lai, Z., Zhang, S., Aronica, S., Cooper, S., Bigsby, R. M., Steinmetz, R., Engle, S. J., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.8.1517 · Cited by 172
“A recent study using mice with a disrupted m opioid receptor gene demonstrated the central role of this receptor in opioid-mediated pain relief (5).”
BackgroundInfluentialPhilippe, D., Dubuquoy, L., Groux, H., Brun, V., Chuoï-Mariot, M. T. V., Gaveriaux-Ruff, C., Colombel, J.-F., Kieffer, B. L., & Desreumaux, P. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16750 · Cited by 171
Self-citationStucky, C. L., Gold, M. S., & Zhang, X. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211373398 · Cited by 165
Hill, R., Disney, A., Conibear, A., Sutcliffe, K., Dewey, W., Husbands, S., Bailey, C., Kelly, E., & Henderson, G. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14224 · Cited by 165
“Current therapeutically useful opioid ligands such as morphine produce their analgesic and respiratory depressant effects through activation of the μ-opioid receptor (μ receptor) (Matthes et al., 1996).”
BackgroundOpioid analgesics as noncompetitive N-methyl-d-aspartate (NMDA) antagonists
Ebert, B., Thorkildsen, C., Andersen, S., Christrup, L. L., & Hjeds, H. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00088-4 · Cited by 164
Goeldner, C., Lutz, P.-E., Darcq, E., Halter, T., Clesse, D., Ouagazzal, A.-M., & Kieffer, B. L. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.021 · Cited by 163
“Somatic withdrawal signs (jumps, paw tremors, wet dog shakes, sniffings) were scored for 25 min (38,39).”
BackgroundSelf-citationJanicki, P. K., Schuler, G., Francis, D., Bohr, A., Gordin, V., Jarzembowski, T., Ruiz-Velasco, V., & Mets, B. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000231634.20341.88 · Cited by 166
“The human -opioid receptor (MOR), coded by the OPRM1 gene, is a primary candidate for the pharmacogenetic variability of the clinical effects of opioid analgesics because it is the major site of action for the most common opioids currently used (3,4).”
BackgroundSarton, E., Teppema, L. J., Olievier, C., Nieuwenhuijs, D., Matthes, H. W. D., Kieffer, B. L., & Dahan, A. (2001) · Anesthesia & Analgesia · doi:10.1097/00000539-200112000-00031 · Cited by 159
“Mice with a disruption of Exon 2 of the MOR gene (MOR/) and WT animals of the same mouse strain have been reported previously (8, 16 ).”
BackgroundSelf-citationGarrido, M. J., & Trocóniz, I. F. (1999) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00043-5 · Cited by 160
Zhang, H., Kranzler, H. R., Yang, B.-Z., Luo, X., & Gelernter, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002035 · Cited by 160
Burford, N. T., Clark, M. J., Wehrman, T. S., Gerritz, S. W., Banks, M. N., O’Connell, J. C., Traynor, J. R., & Alt, A. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300393110 · Cited by 178
“Opioid receptors are key targets in the management of pain and morphine and its derivatives induce pain relief by acting as agonists at opioid receptors, especially the μ-opioid receptor (5, 6).”
BackgroundAnesthesia and Analgesia for Laboratory Rodents
Gaertner, D. J., Hallman, T., Hankenson, F. C., & Batchelder, M. (2008) · Elsevier eBooks · doi:10.1016/b978-012373898-1.50014-0 · Cited by 201
Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits
Wang, D., Tawfik, V. L., Corder, G., Low, S. A., François, A., Basbaum, A. I., & Scherrer, G. (2018) · Neuron · doi:10.1016/j.neuron.2018.03.002 · Cited by 156
“…(Scherrer et al., 2006), Oprm1mCherry/mCherry mice (Erbs et al., 2015), Oprd1 knockout mice (Filliol et al., 2000), Oprm1 knockout mice (Matthes et al., 1996), Oprd1flox/flox mice (Gaveriaux-Ruff et al., 2011), Vglut2Cre and VgatCre mice (Vong et al., 2011), SomCre mice (Taniguchi et…”
BackgroundTransgenic Approach to the Study of Body Weight Regulation
Inui, A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01435-2 · Cited by 174
“…laboratories, and the main biological actions of morphine were abolished in the mutant mice, including analgesia, reward and physical dependence (Matthes et al., 1996; Kieffer, 1999). k-Opioid deficient mice were reported to have a modified nociceptive threshold in response to visceral pain…”
Majumdar, S., Grinnell, S., Le Rouzic, V., Burgman, M., Polikar, L., Ansonoff, M., Pintar, J., Pan, Y.-X., & Pasternak, G. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115231108 · Cited by 154
Raehal, K. M., & Bohn, L. M. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-41199-1_22 · Cited by 154
“The generation of genetic knockout mice has demonstrated that the majority of clinically used opioids including morphine produce their pharmacological effects primarily by activating the MOR (Matthes et al. 1996; Sora et al. 1997; Roy et al. 1998; Kieffer 1999; Kieffer and GaveriauxRuff 2002).”
BackgroundZhang, H., Luo, X., Kranzler, H. R., Lappalainen, J., Yang, B.-Z., Krupitsky, E., Zvartau, E., & Gelernter, J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl024 · Cited by 154
“Disruption of the MOR gene (Oprm) in mice abolishes morphine-induced analgesia, place-preference activity and physical-dependence, even in the presence of intact d-and k-opioid receptors (DOR and KOR) (3,4).”
BackgroundTrafton, J. A., Abbadie, C., Marek, K. W., & Basbaum, A. I. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08578.2000 · Cited by 154
“Also, mice lacking the MOR have been shown to have normal behavioral responses to acute noxious thermal stimuli (Matthes et al., 1996), further suggesting that endogenous m-opioids are not involved in normal acute nociceptive responses.”
BackgroundLigand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling
Melief, E. J., Miyatake, M., Bruchas, M. R., & Chavkin, C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000751107 · Cited by 153
Opioid receptor and peptide gene polymorphisms: potential implications for addictions
LaForge, K. S., Yuferov, V. P., & Kreek, M. J. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00819-0 · Cited by 167
μ-Opioid Receptor Knockout Mice Do Not Self-Administer Alcohol
Roberts, A. J., McDonald, J. S., Heyser, C. J., Kieffer, B. L., Matthes, H. W. D., Koob, G. F., & Gold, L. H. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39326-7 · Cited by 138
Self-citationμ-opioid modulation of HIV-1 coreceptor expressionand HIV-1 replication
Steele, A. D., Henderson, E. E., & Rogers, T. J. (2003) · Virology · doi:10.1016/s0042-6822(03)00015-1 · Cited by 166
“The -opioid receptor class is associated with the analgesic properties of morphine, based on pharmacological data as well as the observation that morphine-induced analgesia is absent in -opioid receptor knockout mice (Matthes et al., 1996).”
BackgroundTopographical organization of projections from the subiculum to the hypothalamus in the rat
Kishi, T., Tsumori, T., Ono, K., Yokota, S., Ishino, H., & Yasui, Y. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000403)419:2<205::aid-cne5>3.0.co;2-0 · Cited by 117
Cui, Y., Ostlund, S. B., James, A. S., Park, C. S., Ge, W., Roberts, K. W., Mittal, N., Murphy, N. P., Cepeda, C., Kieffer, B. L., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3622 · Cited by 148
“(b) CPP is restored in Rescue mouse littermates, but such a rescue effect is eliminated by the genetic removal of the MOR transgene in striatal MSNs in Rescuecre mice (F(4, 68) = 5.”
BackgroundSelf-citationLigand‐directed signalling within the opioid receptor family
Pradhan, A. A., Smith, M. L., Kieffer, B. L., & Evans, C. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02075.x · Cited by 148
“In mice null for the m opioid receptor, morphine loses both its analgesic efficacy and rewarding properties (Matthes et al., 1996; Contet et al., 2004), as well as many other well-described biological activities (for review, see Gaveriaux-Ruff and Kieffer, 2002), demonstrating that this receptor mediates multiple effe…”
BackgroundSelf-citationMU-opioid receptor-knockout mice: role of μ-opioid receptor in morphine mediated immune functions
Roy, S., Barke, R. A., & Loh, H. H. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00212-5 · Cited by 148
Neuropeptides and sexual behaviour
Argiolas, A. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00068-8 · Cited by 166
Charbogne, P., Kieffer, B. L., & Befort, K. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.028 · Cited by 147
Self-citationSamaco, R. C., Mandel-Brehm, C., McGraw, C. M., Shaw, C. A., McGill, B. E., & Zoghbi, H. Y. (2012) · Nature Genetics · doi:10.1038/ng.1066 · Cited by 145
Genes Associated With Addiction: Alcoholism, Opiate, and Cocaine Addiction
Kreek, M. J., Nielsen, D. A., & LaForge, K. S. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:085 · Cited by 159
Ribeiro, S. C. M., Kennedy, S. E., Smith, Y. R., Stohler, C. S., & Zubieta, J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.011 · Cited by 166
“…devoid of A-opioid receptors or the endogenous opioid peptide h-endorphin point to reductions in the capacity to suppress responses to pain signals (Matthes et al., 1996; Sora et al., 1997), stress-induced analgesia (Rubinstein et al., 1996), and more recently, exaggerated anxiety-like responses…”
BackgroundNovelty Seeking and Drug Addiction in Humans and Animals: From Behavior to Molecules
Wingo, T., Nesil, T., Choi, J.-S., & Li, M. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9636-7 · Cited by 144
“ample, Matthes and colleagues showed that mice lacking this receptor subtype do not respond the rewarding effects of morphine (Matthes et al. 1996).”
Daniels, S. E., Upmalis, D. H., Okamoto, A., Lange, C., & Häeussler, J. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902728183 · Cited by 144
“Male 12 (10) 18 (15) 13 (11) 19 (16) 15 (12)”
Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts
Szeto, C. Y. K., Tang, N. L. S., Lee, D. T. S., & Stadlin, A. (2001) · Neuroreport · doi:10.1097/00001756-200105080-00011 · Cited by 144
Are μ-opioid receptor polymorphisms important for clinical opioid therapy?
Lötsch, J., & Geißlinger, G. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.006 · Cited by 146
Neuropeptides and central control of sexual behaviour from the past to the present: A review
Argiolas, A., & Melis, M. R. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.006 · Cited by 161
Morphine‐6‐glucuronide: Actions and mechanisms
Kilpatrick, G. J., & Smith, T. W. (2005) · Medicinal Research Reviews · doi:10.1002/med.20035 · Cited by 159
Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity
Gomes, I., Fujita, W., Gupta, A., Saldanha, S. A., Negri, A., Pinello, C. E., Eberhart, C., Roberts, E., Filizola, M., Hodder, P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222044110 · Cited by 154
“S with mice lacking opioid receptors show that the antinociceptive actions of clinically administered opioids, such as morphine or fentanyl, involve the activation of μ-opioid receptors (μORs) (1).”
BackgroundHayashida, M., Nagashima, M., Satoh, Y., Katoh, R., Tagami, M., Ide, S., Kasai, S., Nishizawa, D., Ogai, Y., Hasegawa, J., et al. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1605 · Cited by 142
Localization of Endomorphin-2-Like Immunoreactivity in the Rat Medulla and Spinal Cord
Martin‐Schild, S., Zadina, J. E., Gerall, A. A., Vigh, S., & Kastin, A. J. (1997) · Peptides · doi:10.1016/s0196-9781(97)00320-3 · Cited by 140
Metadata
- Authors
- Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., & Kieffer, B. L.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- University of Surrey (GB)
- Institut de génétique et de biologie moléculaire et cellulaire (FR)
- Inserm (FR)
- Venue
- Nature
- Published
- 1996-10
- Volume
- 383
- Issue
- 6603
- Pages
- 819-823
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051746492
- Cited by
- 1,722
- References
- 25
- Citations by year
- 2026: 36 · 2025: 40 · 2024: 45 · 2023: 52 · 2022: 53 · 2021: 56 · 2020: 59 · 2019: 56 · 2018: 53 · 2017: 43 · 2016: 59 · 2015: 53 · 2014: 60 · 2013: 65 · 2012: 58
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- mu-opioid receptor, morphine, analgesia, opioid reward, place preference, opioid withdrawal, physical dependence, knockout mice, delta opioid receptor, kappa opioid receptor, opioid system, pain management
- MeSH terms
- Analgesics, Animals, Behavior, Animal, Cell Line, Enkephalins, Mice, Inbred C57BL, Morphine, Morphine Dependence, Narcotics, Reward, Substance Withdrawal Syndrome, Gene Deletion, Receptors, Opioid, mu, Receptors, Opioid, delta, Receptors, Opioid, kappa, Mice, Knockout, Enkephalin, Ala(2)-MePhe(4)-Gly(5)-, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.